20
Participants
Start Date
December 5, 2025
Primary Completion Date
December 7, 2028
Study Completion Date
June 8, 2029
Tucatinib (ONT-380)
Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
Trastuzumab (Herceptin)
Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
Institut Paoli-Calmettes, Marseille
Polyclinique Bordeaux Nord Aquitaine, Bordeaux
Chu Dupuytren- Limoges, Limoges
Centre Antoine Lacassagne, Nice
CHU de Nîmes, Nîmes
Centre Eugène Marquis, Rennes
Institut Curie_ Site Saint-Cloud, Saint-Cloud
Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole Claudius Regaud, Toulouse
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy